+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Systemic Sclerosis - Global Drug Forecast and Market Analysis to 2030

  • ID: 5348003
  • Report
  • May 2021
  • Region: Global
  • 160 pages
  • GlobalData

FEATURED COMPANIES

  • AbbVie Inc
  • Boehringer Ingelheim
  • Bristol-Myers Squibb Co
  • Civi Biopharma Inc
  • Eicos Sciences Inc
  • F. Hoffmann-La Roche Ltd
  • MORE
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

Systemic sclerosis (SSc) is a rare, multisystem autoimmune disease that causes progressive fibrosis of the skin and internal organs, as well as vascular dysfunction. The presentation of the disease is heterogeneous, both in the organ systems affected and the overall severity of symptoms. The most common complications of SSc include digital vasculopathy (Raynaud’s phenomenon and digital ulcers), skin fibrosis, lung fibrosis or interstitial lung disease (ILD), pulmonary arterial hypertension, gastrointestinal issues, arthritis, myopathy, and scleroderma renal crisis. As there are no systemic disease-modifying therapies currently available that significantly alter the course of the disease, the SSc treatment paradigm is to manage complications within individual organ systems as they occur.

The publisher's report and forecast model focus specifically on the treatment of SSC-associated digital vasculopathy, skin fibrosis, and ILD. Most of the drugs used to treat these disease manifestations are decades-old generic agents that have been repurposed from other indications, including immunosuppressive agents (such as methotrexate, mycophenolate mofetil, and cyclophosphamide) and vasodilative cardiovascular drugs (such as calcium channel blockers, PDE5 inhibitors, and prostacyclin analogs). The vast majority of SSc therapies are used off-label. However, there has recently been a major shift in the SSc market landscape, and new players are beginning to enter the space.

The publisher projects that the global SSc market, which comprises the seven major pharmaceutical markets (7MM) (US, France, Germany, Italy, Spain, UK, and Japan), will experience strong growth during the forecast period, at a Compound Annual Growth Rate (CAGR) of 14.0%, with sales growing from $498.0M in 2020 to $1.8B in 2030. Global growth in the SSc market will be driven by uptake of Boehringer Ingelheim’s (BI) recently launched Ofev (nintedanib) and Roche/Genentech’s Actemra/RoActemra (tocilizumab) for the treatment of SSc-associated ILD, along with the anticipated approval and launch of six pipeline therapies. This growth will be limited by sales erosion from generic nintedanib and biosimilars.

In this report, the publisher focuses its market forecast analysis on six Phase III and late Phase II products expected to be licensed for SSc between 2020 and 2030. These include four small molecule drugs - Civi BioPharma/Eicos Sciences’ IV Civi-030 (iloprost), Horizon Therapeutics’ HZN-825, Kadmon Corporation’s belumosudil mesylate, and Mitsubishi Tanabe Pharma’s dersimelagon - and two monoclonal antibodies currently marketed for the treatment of PSO and PsA - Kyowa Kirin’s Lumicef (brodalumab) and J&J’s Tremfya (guselkumab).

Although key opinion leaders (KOLs) interviewed by the publisher were pleased to see such an innovative late-stage pipeline for SSc, they did highlight major, lingering unmet needs in the field. These include needs for the development of disease-modifying and anti-fibrotic therapies, earlier diagnosis and treatment, and improved prognostic biomarkers. KOLs were optimistic about the future of SSc but believed there was significant work left to be done in this space.

Key Highlights
  • The greatest drivers of growth in the global SSc market will be the recent launches of Ofev and Actemra/RoActemra for the treatment of ILD associated with SSc, the anticipated approval and launch of six pipeline therapies, a steadily climbing diagnosed prevalence rate, and a growing overall treatment rate due to growing access to new therapies.
  • The main barriers to growth in the SSc market will be significant market share erosion from biosimilars and nintedanib generics as well as a historical treatment paradigm that focuses on the off-label use of inexpensive generic products.
  • KOLs expressed enthusiasm for the six pipeline agents in development. Of these agents, KOLs were most interested in Civi Biopharma/Eicos Sciences’ Civi-030, Horizon Therapeutics’ HZN-825, and Kadmon Corporation’s belumosudil mesylate.
  • The most important unmet needs in SSc are those for the development of disease-modifying and anti-fibrotic therapies, earlier diagnosis and treatment, and improved prognostic biomarkers.
Key Questions Answered

For the first time ever, treatment options for patients with SSc are beginning to expand.
  • What impact will the recently launched drugs, Ofev and Actemra/RoActemra, have on the treatment of SSc throughout the 7MM?
  • What pipeline agents are currently in late-stage clinical development, and which are the most promising?
Growing interest in SSc by the pharmaceutical industry is transforming research and development practices in the field.
  • What are the main R&D trends in the SSc market and which companies are leading the way?
  • How is clinical trial design for SSc changing and in what ways does it differ depending on disease manifestation?
KOLs interviewed by the publisher have indicated that there are still many remaining unmet needs within the SSc indication.
  • What are the main unmet needs in the SSc market?
  • How can the pharmaceutical industry address these needs?
  • To what degree will the therapies under development fulfill these unmet needs?
Scope
  • Overview of SSc including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and treatment guidelines.
  • Topline SSc therapeutics market revenue, annual cost of therapy, and major pipeline product sales in the forecast period.
  • Key topics covered include current treatment and pipeline therapies, unmet needs and opportunities, and the drivers and barriers affecting SSc therapeutics sales in the 8MM.
  • Pipeline analysis: Comprehensive data split across different phases, emerging novel trends under development, and detailed analysis of late-stage pipeline drugs.
  • Analysis of the current and future market competition in the global SSc therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.
Reasons to Buy

The report will enable you to -
  • Develop and design your in-licensing and out-licensing strategies, using a detailed overview of current pipeline products and technologies to identify companies with the most robust pipelines.
  • Develop business strategies by understanding the trends shaping and driving the global SSc therapeutics market.
  • Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global SSc market in the future.
  • Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
  • Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
  • Track drug sales in the global SSc therapeutics market from 2020-2030.
  • Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • AbbVie Inc
  • Boehringer Ingelheim
  • Bristol-Myers Squibb Co
  • Civi Biopharma Inc
  • Eicos Sciences Inc
  • F. Hoffmann-La Roche Ltd
  • MORE
1 Systemic Sclerosis: Executive Summary
1.1 New Drug Approvals Expected to Drive Strong Growth in SSc
1.2 Current SSc Market Dynamics Reflect a Blend of New and Old R&D Strategies
1.3 While Outlook in SSc Improves, Opportunities Remains to Improve Patient Outcomes
1.4 SSc Pipeline Targets the Skin, Lungs, and Vasculature with New MOAs
1.5 What Do Physicians Think?

2 Introduction
2.1 Catalyst
2.2 Related Reports
2.3 Upcoming Related Reports

3 Disease Overview
3.1 Etiology and Pathophysiology
3.1.1 Etiology
3.1.2 Pathophysiology
3.2 Disease Classification

4 Epidemiology
4.1 Disease Background
4.2 Risk Factors and Comorbidities
4.3 Global and Historical Trends
4.4 7MM Forecast Methodology
4.4.1 Sources
4.4.2 Forecast Assumptions and Methods
4.4.3 Forecast Assumptions and Methods: Diagnosed Prevalent Cases of SSc - 7MM
4.4.4 Forecast Assumptions and Methods: Diagnosed Prevalent Cases of SSc by Subtype
4.4.5 Diagnosed Prevalent Cases of SSc by Digital Vasculopathy
4.4.6 Diagnosed Prevalent Cases of by other Internal Organ Involvement and Comorbidities
4.5 Epidemiological Forecast for Systemic Sclerosis (2020-2030)
4.5.1 Diagnosed Prevalent Cases of SSc
4.5.2 Age-Specific Diagnosed Prevalent Cases of SSc
4.5.3 Sex-Specific Diagnosed Prevalent Cases of SSc
4.5.4 Diagnosed Prevalent Cases of SSc by Subtype
4.5.5 Diagnosed Prevalent Cases of SSc by Digital Vasculopathy
4.5.6 Diagnosed Prevalent Cases of SSc by Other Internal Organ Involvement
4.5.7 Diagnosed Prevalent Cases of SSc with Comorbid Malignancy
4.6 Discussion
4.6.1 Epidemiological Forecast Insight
4.6.2 COVID-19 Impact
4.6.3 Limitations of the Analysis
4.6.4 Strengths of the Analysis

5 Disease Management
5.1 Diagnosis
5.2 Treatment
5.2.1 Digital Vasculopathy
5.2.2 Skin and Lung Fibrosis
5.2.3 Other Organ Involvement

6 Competitive Assessment
6.1 Overview

7 Unmet Needs and Opportunity Assessment
7.1 Overview
7.2 Lack of Disease-Modifying Therapies
7.3 Lack of Anti-Fibrotic Drugs
7.4 Earlier Referral and Treatment
7.5 Improved Prognostic Biomarkers

8 R&D Strategies
8.1 Overview
8.1.1 Repurposing of Drugs Used for Autoimmune and Cardiovascular Diseases
8.1.2 Big Pharma Forges Ahead in SSc-ILD Approvals
8.1.3 New Mechanisms of Action for Early Dc-SSc
8.2 Clinical Trial Design
8.2.1 Early Dc-SSc
8.2.2 SSc-ILD
8.2.3 Digital Vasculopathy

9 Pipeline Assessment
9.1 Overview
9.2 Promising Drugs in Clinical Development
9.2.1 Civi-030
9.2.2 HZN-825
9.2.3 Belumosudil Mesylate
9.2.4 Dersimelagon
9.2.5 Lumicef and Tremfya
9.3 Other Drugs of Note
9.3.1 Lenabasum

10 Pipeline Valuation Analysis
10.1 Overview
10.2 Competitive Assessment
10.2.1 Skin Fibrosis
10.2.2 Lung Fibrosis
10.2.3 Digital Vasculopathy

11 Current and Future Players
11.1 Overview
11.2 Deal-Making Trends

12 Market Outlook
12.1 Global Markets
12.1.1 Forecast
12.1.2 Drivers and Barriers - Global Issues
12.2 US
12.2.1 Forecast
12.2.2 Key Events
12.2.3 Drivers and Barriers
12.3 5EU
12.3.1 Forecast
12.3.2 Key Events
12.3.3 Drivers and Barriers
12.4 Japan
12.4.1 Forecast
12.4.2 Key Events
12.4.3 Drivers and Barriers

13 Appendix

List of Tables
Table 1: SSc Key Metrics in the 7MM
Table 2: Classification Groups for SSc
Table 3: Risk Factors and Comorbidities for SSc
Table 4: Diagnosed Prevalent Cases of SSc by Other Internal Organ Involvement
Table 5: 2013 ACR/EULAR Criteria for the Classification of SSc
Table 6: Frequency and Clinical Correlation of Select SSc-associated Nuclear Autoantibodies
Table 7: Treatment Guidelines for SSc
Table 8: Comparison of Provisional ACR-CRISS and Revised ACR-CRISS
Table 9: Key Deals in SSc Market, 2016-2021
Table 10: SSc Market - Global Drivers and Barriers, 2020-2030
Table 11: Key Events Impacting Sales for SSc in the US, 2020-2030
Table 12: SSc Market - Drivers and Barriers in the US, 2020-2030
Table 13: Key Events Impacting Sales for SSc in the 5EU, 2020-2030
Table 14: SSc Market - Drivers and Barriers in the 5EU, 2020-2030
Table 15: Key Events Impacting Sales for SSc in Japan, 2020-2030
Table 16: SSc Market - Drivers and Barriers in Japan, 2020-2030
Table 17: High-Prescribing Physicians (non-KOLs) Surveyed, By Country

List of Figures
Figure 1: Global (7MM) Sales Forecast by Country for SSc in 2020 and 2030
Figure 2: Analysis of the Company Portfolio Gap in SSc During the Forecast Period
Figure 3: Competitive Assessment of the Marketed and Pipeline Drugs Benchmarked Against the SOCs for SSc-Associated Skin Fibrosis, MMF and MTX
Figure 4: Competitive Assessment of the Marketed and Pipeline Drugs Benchmarked Against the SOCs for SSc-Associated Lung Fibrosis, MMF and Ofev
Figure 5: Competitive Assessment of the Marketed and Pipeline Drugs Benchmarked Against the SOC for SSc-Associated Digital Vasculopathy, Generic Epoprostenol
Figure 6: SSc Pathophysiology and Associated Therapeutic Mechanisms
Figure 7: 7MM, Diagnosed Prevalence of SSc, Men and Women, %, Ages ≥18 Years, 2020
Figure 8: 7MM, Sources Used and Not Used to Forecast the Diagnosed Prevalent Cases of SSc
Figure 9: 7MM, Sources Used to Forecast the Diagnosed Prevalent Cases of SSc by Subtype
Figure 10: 7MM, Sources Used to Forecast the Diagnosed Prevalent Cases of SSc by Digital Vasculopathy
Figure 11: 7MM, Sources Used to Forecast the Diagnosed Prevalent Cases of SSc by Other Internal Organ Involvement - ILD, PAH, and Kidney Disease
Figure 12: 7MM, Sources Used to Forecast the Diagnosed Prevalent Cases of SSc by Other Internal Organ Involvement - Cardiac Involvement, Gastrointestinal Involvement, Musculoskeletal Involvement, and Neuromuscular Involvement; and Comorbidity - Malignancy
Figure 13: 7MM, Diagnosed Prevalent Cases of SSc, N, Both Sexes, Ages ≥18 Years, 2020
Figure 14: 7MM, Diagnosed Prevalent Cases of SSc by Age, N, Both Sexes, 2020
Figure 15: 7MM, Diagnosed Prevalent Cases of SSc by Sex, N, Ages ≥18 Years, 2020
Figure 16: 7MM, Diagnosed Prevalent Cases of SSc by Subtype, N, Both Sexes, Ages ≥18 Years, 2020
Figure 17: 7MM, Diagnosed Prevalent Cases of SSc by Digital Vasculopathy, N, Both Sexes, Ages ≥18 Years, 2020
Figure 18: 7MM, Diagnosed Prevalent Cases of SSc with Comorbid Malignancy, N, Both Sexes, Ages ≥18 Years, 2020
Figure 19: General Treatment Algorithm for SSc-Associated Digital Vasculopathy, 2021
Figure 20: General Treatment Algorithm for SSc-Associated Skin and Lung Fibrosis, 2021
Figure 21: Unmet Needs and Opportunities in SSc
Figure 22: Overview of the Development Pipeline in SSc
Figure 23: Key Late-Stage Trials for the Promising Pipeline Agents that the Publisher Expects Be Licensed for SSc in the 7MM During the Forecast Period
Figure 24: Competitive Assessment of the Marketed and Pipeline Drugs Benchmarked Against the SOCs for SSc-Associated Skin Fibrosis, MMF and MTX
Figure 25: Competitive Assessment of the Marketed and Pipeline Drugs Benchmarked Against the SOCs for SSc-Associated Lung Fibrosis, MMF and Ofev
Figure 26: Competitive Assessment of the Marketed and Pipeline Drugs Benchmarked Against the SOC for SSc-Associated Digital Vasculopathy, Generic Epoprostenol
Figure 27: Analysis of the Company Portfolio Gap in SSc During the Forecast Period
Figure 28: Global (7MM) Sales Forecast by Country for SSc in 2020 and 2030
Figure 29: Global (7MM) Sales Forecast by Drug Class for SSc in 2020 and 2030
Figure 30: Sales Forecast by Drug Class for SSc in the US in 2020 and 2030
Figure 31: Sales Forecast by Drug Class for SSc in the 5EU in 2020 and 2030
Figure 32: Sales Forecast by Drug Class for SSc in Japan in 2020 and 2030
Note: Product cover images may vary from those shown

A selection of companies mentioned in this report includes:

  • AbbVie Inc
  • Boehringer Ingelheim
  • Bristol-Myers Squibb Co
  • Chugai Pharmaceutical Co Ltd
  • Civi Biopharma Inc
  • Corbus Pharmaceuticals Inc
  • Eicos Sciences Inc
  • F. Hoffmann-La Roche Ltd
  • Genentech Inc
  • Horizon Therapeutics Plc
  • Janssen
Note: Product cover images may vary from those shown
Adroll
adroll